Interstitial Lung Disease With CA19-9 Elevation After Oxaliplatin and Capecitabine Adjuvant Therapy for Ileocecal Carcinoma:Report of One Case.
10.3881/j.issn.1000-503X.16328
- Author:
Wen-Jing YANG
1
;
Guo-Wang YANG
1
;
Ying LI
1
;
Hao WANG
1
;
Lin YANG
1
;
Wei-Ru XU
1
Author Information
1. Department of Oncology,Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China.
- Publication Type:Case Reports
- Keywords:
CA19-9;
capecitabine;
interstitial lung disease;
oxaliplatin;
recurrence and metastasis
- MeSH:
Humans;
CA-19-9 Antigen/blood*;
Capecitabine;
Cecal Neoplasms/drug therapy*;
Chemotherapy, Adjuvant;
Deoxycytidine/administration & dosage*;
Fluorouracil/administration & dosage*;
Lung Diseases, Interstitial/blood*;
Organoplatinum Compounds/administration & dosage*;
Oxaliplatin
- From:
Acta Academiae Medicinae Sinicae
2025;47(4):660-665
- CountryChina
- Language:English
-
Abstract:
Both carcinoembryonic antigen and CA19-9 are considered as predictive markers of intestinal cancer recurrence and metastasis.In addition,CA19-9 elevation is considered as a predictive marker of connective tissue disease-related interstitial lung disease.The incidence of oxaliplatin and capecitabine-associated interstitial lung disease is low,and there is no report about CA19-9 as a predictive marker of oxaliplatin and capecitabine-associated interstitial lung disease.This paper reports a case of interstitial lung disease with CA19-9 elevation caused by oxaliplatin and capecitabine adjuvant therapy for ileocecal carcinoma.The change trend of serum carcinoembryonic antigen in this patient was consistent with tumor recurrence and metastasis,and that of serum CA19-9 was consistent with the severity of interstitial lung disease.Therefore,CA19-9 elevation after intestinal cancer surgery does not necessarily indicate the tumor recurrence and metastasis,and attention should be paid to the possibility of oxaliplatin and capecitabine-associated interstitial lung disease.
